Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T02677
|
||||
Former ID |
TTDC00273
|
||||
Target Name |
Baculoviral IAP repeat-containing protein 5
|
||||
Gene Name |
BIRC5
|
||||
Synonyms |
Apoptosis inhibitor 4; Apoptosis inhibitor survivin; Survivin; BIRC5
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
Non-small cell lung cancer [ICD10: C33-C34] | |||||
Ovarian cancer [ICD9: 183; ICD10: C56] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Function |
May play a role in neoplasia. May counteract a default induction of apoptosis in g2/m phase. Interacts with tubulin. Inhibitor of caspase-3 and caspase-7.
|
||||
BioChemical Class |
Inhibitor of apoptosis
|
||||
Target Validation |
T02677
|
||||
UniProt ID | |||||
Sequence |
MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFC
FKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNK KKEFEETAKKVRRAIEQLAAMD |
||||
Drugs and Mode of Action | |||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Hippo signaling pathway | ||||
Hepatitis B | |||||
Pathways in cancer | |||||
Colorectal cancer | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
Pathway Interaction Database | Aurora B signaling | ||||
Validated targets of C-MYC transcriptional activation | |||||
FOXM1 transcription factor network | |||||
Aurora A signaling | |||||
Reactome | Separation of Sister Chromatids | ||||
Resolution of Sister Chromatid Cohesion | |||||
RHO GTPases Activate Formins | |||||
Mitotic Prometaphase | |||||
WikiPathways | IL-4 Signaling Pathway | ||||
Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
Mitotic Metaphase and Anaphase | |||||
Mitotic Prometaphase | |||||
Apoptosis | |||||
Interleukin-11 Signaling Pathway | |||||
Apoptosis Modulation and Signaling | |||||
References | |||||
Ref 522696 | ClinicalTrials.gov (NCT00923312) Trial of an RNActive-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC). U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.